Latest filing published 08 Sept 2026 for Phathom Pharmaceuticals, Inc., €3,590.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Robert Charles Breedlove: trading record in brief
Robert Charles Breedlove discloses dealings in Phathom Pharmaceuticals, Inc. to SEC (Form 4). Over a trading history stretching from 16 July 2025 to 3 September 2026, the count stands at 11 filings.
No open-market purchase appears, only 3 sales worth €23k. Other entries cover 8 share grants.
On 8 September 2026 came the latest disclosure, a share grant for €3,590 in Phathom Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Robert Charles Breedlove
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 460 shares@ US$9.05Common StockSEC:0001193125-26-385250:0
- 1,555 shares@ US$11.0350.0020% mcap29.9% of flowCommon StockSEC:0001193125-26-306165:0
- 13,000 shares0Common StockSEC:0001193125-26-088730:0
- 776 shares@ US$13.6125.5% of flowCommon StockSEC:0001193125-26-021164:0
- 230 shares@ US$16.2812.1% of flowCommon StockSEC:0001193125-25-327135:0
- 524 shares@ US$13.5126.6% of flowCommon StockSEC:0001193125-25-267057:0
- 461 shares@ US$12.09100.0% of flowCommon StockSEC:0000950170-25-113822:0
- 1,692 shares@ US$8.363971.8% of flowCommon StockSEC:0000950170-25-096917:0
8 of 8 declarations
